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Abstract. Breast cancer (BC) recovery has increased in
recent years thanks to efforts of Omics-based research in this
field. However, despite the important results obtained, BC
remains a complex multifactorial pathology that is difficult
to treat appropriately. Caveolin-1 (CAV1), the basic
constituent protein of specialized plasma membrane
invaginations called caveolae, is emerging as a potential
therapeutic biomarker in BC. This factor may modulate BC
response to chemotherapy and radiation therapy. In addition,
recent reports describe the key role of CAV1 during cell
response to oxidative stress. The aim of the present review
was to describe the biological roles of CAV1 in BC
considering its contrasting dual functions as an oncogene
and as a tumor suppressor. In addition, we report on how
CAV1 may contribute to tumor cell response to ionizing
radiation treatment. Finally, new roles of CAV1 in BC both
on epithelium and stroma may be useful as prognostic
indicators for patient treatment and help clinicians in the
selection of the best personalized therapy. 
It is well-known that breast cancer (BC) is not a single
disease but a neoplastic disorder which is highly
heterogeneous at both the molecular and clinical level,
comprising of different molecular subtypes that generally
correspond to different prognoses and responsiveness to
therapy (1-4).
Although therapeutic treatment plans for BC have recently
made great progress, recurrence and death rates remain
unacceptably high (5). Molecular biomarkers of BC could
help clinicians identify new diagnostic and therapeutic
strategies for predicting clinical outcome and response to
therapy schedule (6).
Caveolae are plasma membrane invaginations rich in
proteins involved in the pathogenesis of several human
diseases that are emerging as potential BC biomarkers (7).
The formation and maintenance of caveolae is primarily due
to caveolin proteins. The caveolin protein family consists of
the following three members: caveolin-1 (CAV1), CAV2, and
CAV3. CAV1 is widely expressed in various tissues, whereas
CAV3 is muscle-specific. CAV2 is co-expressed with CAV1
and requires CAV1 for stabilization and plasma membrane
localization (8).
Caveolin-1 and Breast Cancer
CAV1 plays an important role in carcinogenesis because it
interacts with many factors involved in mitogenic signaling,
angiogenesis, and senescence processes. In this direction,
many data describe its involvement in BC as a possible
molecular target, able to predict the patient’s response to
treatment (9).
CAV1 protein coats the caveolae, acting as a scaffolding
protein to organize and concentrate specific lipids (e.g.
cholesterol and glycosphingolids) and signaling molecules,
such as SRC-like kinases, Harvey rat sarcoma viral oncogene
homolog (H-RAS), endothelial nitric oxide synthase, and G-
proteins, within caveolae membranes (10-11). The CAV1
scaffolding domain (CSD; amino acid residues 82-101)
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interacts with the binding motif contained within the
catalytic site of specific signaling molecules. On binding it
forms an inactive complex. In fact, following an appropriate
stimulus, CAV1 is released from the binding motif, causing
the propagation of downstream signals. More precisely, it has
been reported that the CSD inhibits SRC family tyrosine
kinases (i.e, c-SRC/FYN), epidermal growth factor receptor
(EGFR), ERB-B2 receptor tyrosine kinase 2 (alias
HER2/neu), protein kinase C (PKC) and extracellular signal-
regulated kinase (ERK) proteins(10-12). CAV1 is also able
to maintain a specific active v-Akt murine thymoma viral
oncogene homolog 1 (AKT) status able to guide pro-survival
signaling. This action is probably facilitated by inhibitory
binding of the AKT-phosphatase protein 1 and -2A (PP1A
and PP2A) to the CSD domain of CAV1 (13).
A link between CAV1 and E-cadherin is also reported.
CAV1 seems to inhibit the expression of the anti-apoptotic
factor Survivin only in the presence of E-cadherin via the
wingless-type MMTV integration site family (Wnt)/β-
catenin-pathway, with the involvement of cyclo-oxygenase-2
and prostaglandin E2, modulating cancer cell radio-and
chemoresistance (14).
The CAV 1gene is localized at the D7S522 locus on
chromosome 7 (7q31.1). Interestingly, D7S522 spans a
known common fragile site (called FRA7G) that is
frequently deleted in a variety of human neoplastic diseases,
including squamous cell carcinoma, prostate cancer, renal
cell carcinoma, ovarian and colon carcinoma, as well as BC.
This evidence has suggested that the coded protein may act
as a tumor-suppressor at the D7S522 locus (15).
Today, estrogen receptor status (ER) is a well-defined
biomarker routinely tested in BC diagnosis and treatment.
ERα and ERβ are nuclear protein targets of estrogen action,
very important factors for normal development and
maintenance of female characteristics and sexual
reproduction. While ERα is expressed at low levels in
normal mammary epithelial cells, its up-regulation is found
in pre-malignant hyperplasia and during the development of
BC. One-third of human ERα-positive BCs harbor CAV1
mutations (16). In particular, the CAV1 (P132L) mutation,
which causes a proline to leucine change at amino acid
position 132 of the transmembrane domain, is found in more
than half of all ER-positive BC cases (13, 16). This mutation
leads to ERα overexpression and increased sensitivity toward
estrogen therapy, but on the other hand, it could represent an
important risk factor for breast tumor development (13, 17).
Until recently, the role of CAV1 in cancer was strictly
focused on its epithelium-dependent functions, disregarding
completely its effect on the tumor-associated stroma.
However, stromal CAV1 expression has also been reported
as a biomarker predictive of poor prognosis in BC (9, 18-19).
Today, it is well-known that the tumor microenvironment
plays an important role in BC onset and progression (20-21),
in particular, the tumor stroma can drive invasion and
metastasis, hallmarks of malignancy responsible for cancer
treatment failure, recurrence and death. 
Loss of expression of CAV1 in BC-associated fibroblasts
(BCAFs) has been associated with increased tumor
progression, the presence of local metastases and ER
negativity, all features related to poor outcome (18-22).
However, the role of CAV1 in BC is still very controversial
because it has been shown to have a dual opposing role,
acting as a tumor suppressor and as an oncogene.
Tumor Suppressor or Oncogenic Factor?
Many data suggest anti-proliferative and transformation-
suppressive roles of CAV1 in mammary epithelial cells.
Indeed, reduction of CAV1 protein level is a common event in
transformed cell lines, suggesting that it might be inactivated
during tumorigenesis and that it may be associated with
known tumor-suppressor proteins (23, 24). In the MCF7 BC
cell line, CAV1 transfection up-regulates breast cancer 1
(BRCA1) protein expression through a p53-dependent
mechanism. In addition, with a positive feedback mechanism,
BRCA1 protein also increases CAV1 mRNA expression by
promoter gene transactivation (25, 26).
CAV1 is also involved in regulation of phosphatase and
tensin homolog (PTEN), a protein phosphatase with a tumor-
suppressor function (27). Interestingly, ERK1/2 is
compartmentalized within caveolae and the up-regulation of
CAV1 expression down-modulates ERK1/2 kinase activity
(28-30).
CAV1 can also regulate cell-cycle progression by acting
on cyclin D1 protein. More precisely, cyclin D1 is
responsible for the G1 to S phase transition, forming an
active complex that promotes cell-cycle progression by
phosphorylating and inactivating the retinoblastoma (Rb)
factor (31-34). The cyclin D1 gene (CCND1) is amplified or
overexpressed in almost 50% of BC cases. In vitro evidence
has shown that this gene is transcriptionally repressed by
CAV1 overexpression, preventing cell transformation (35).
In general, CAV1 expression correlates positively with the
recovery of cell adhesion and reduced cell motility (36, 37).
CAV1 may have a pro-apoptotic role, indeed, its
overexpression induced apoptotic cell death through
inhibition of PI3-kinase and activation of caspase-3 (38, 39).
Several studies have reported that CAV1 plays a role as a
suppressor of BC metastasis, controlling activity of
metallopeptidases (MMPs) which are able to enhance tumor
invasiveness and metastasis formation (40-42). Metastatic
mammary tumor cells that expressed recombinant CAV1
showed significant reduction in matrigel invasion and
dramatically reduced MMP2 and MMP9 activities (35).
On the other hand, certain data demonstrated that CAV1
may also have oncogenic properties in human cancer
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including breast, colorectal, lung, and other (43). P132L
mutation of CAV1 is believed to cause the mislocalization
and intracellular retention of wild-type CAV1, therefore
acting as a dominant-negative mutant (44). Some reports
described the presence of the P132L mutation in primary
breast tumors whose overexpression in mammary tumor cells
caused a significant increase in cell migration, invasion and
metastasis formation. This genetic alteration is clinically
relevant: patients harboring the P132L mutation have an 82%
chance of cancer recurrence (44-47). Moreover, six CAV1
mutations associated with ERα-positive BC (W128Stop,
Y118H, S136R, I141T, Y148H, and Y148S) were also
described, with an overall frequency of 35%, suggesting that
sporadic CAV1 mutations may act as an initiating event in
BC pathogenesis (16, 48-49).
CAV1: A Putative Marker for Therapeutic 
Choices in Breast Cancer
BC represents a highly heterogeneous group of tumors at
both the clinical and molecular level. The choice of a unique
therapy common to all patients is not possible because of the
presence of several subtypes of BC. Several currently used
therapeutic strategies are based on different receptor status
and tumor stage (2, 6). CAV1 is involved in the response to
chemo- and radiation therapy used in the treatment of BC.
Recent data also show the great involvement of stromal
CAV1 level for predicting BC outcome, indicating how its
modulation in response to oxidative stress may lead to the
choice of the best therapy (50, 51). In particular, it interacts
with the ER and HER2 receptors by modulating their
function and conditioning the response to drugs such as
tamoxifen and trastuzumab. Trastuzumab is a targeted-drug
commonly used for mammary tumors that overexpress the
HER2 receptor. The oncogenic tyrosine kinase receptor
HER2 can transduce strong mitogenic signals during cell
transformation and proliferation by its ability to
heterodimerize with EGF and with ERBB3 (52-53). HER2
inactivation is essential for stopping the proliferation signal.
Elevated levels of HER2 in tumor cells are associated with
its defective endocytosis and deregulation (54). Little is
known on the interaction between CAV1 and HER2
signaling pathways. The kinase domain of HER2 includes a
CAV1-binding motif, EGFR analogous, and a 20-aminoacid
peptide derived from the CSD that can prevent HER2
autophosphorylation and kinase function (54). Caveolae may
well function in the endocytotic pathway for HER2
internalization: the endocytosed molecules may be destined
to migrate to the intracellular compartments for degradation.
Data even suggest HER2 endocytosis to be through a CAV1-
dependent pathway: HER2 may be retained on the cell
surface even after ligand stimulation in caveolae-deficient
BC cells (55). Thus, CAV1 could contribute to inhibition of
growth and proliferation signals from HER2 through its
down-regulation, thereby acting as a tumor suppressor. It was
shown that upon trastuzumab treatment, HER2 was
internalized in the CAV1-expressing SKBR3 BC cell line
(56). This internalization decreased following siRNA-
mediated CAV1 inhibition (56-57). On the other hand,
antibody-dependent cell-mediated cytotoxicity, mediated by
human peripheral blood mononuclear cells towards
trastuzumab-treated and CAV1-transfected SKBR3 cells was
also observed. This effect suggests that enhanced endocytosis
of HER2 through a potential CAV1-dependent pathway is
significant for desensitizing cells to the ADCC-dependent
cytotoxicity of trastuzumab (57-58). For this reason, CAV1
has also been described as one of the potential causes of
resistance to trastuzumab in BC cells. Thus, CAV1 and
caveolae deficiency might be a prognostic or predictive
factor of response to trastuzumab therapy.
Tamoxifen is one of the most effective standard anti-
estrogen therapies for treating ERα-positive BC and
preventing estrogen-dependent growth. Unfortunately,
neoplasia in almost half of the patients under this therapy
become resistant and can quickly recur. As described above,
a relationship between CAV1 and ERα status was reported
in literature. In ERα-positive BC cells, CAV1 has a tumor-
suppressive role (59, 60). In mammary cells, it is a negative
regulator of estrogen-stimulated proliferation through a
decreased expression of its coactivators such as coactivator
protein for AP1 and ER receptor (CAPER), a transcriptional
activator of ERα and JUN/AP1 (59). CAV1 null mammary
epithelial cells showed an increased expression of ERα and
of its co-activator genes (CAPER and forkhead box A1
(FOXA1)), and estrogen hypersensitivity (60). Conversely,
some reports suggested a potential role of CAV1 in the
development of tamoxifen resistance. CAV1-deficient mice
had elevated levels of B23 (nucleophosmin), a nucleolar
marker predictive of tamoxifen resistance (60, 61).
Moreover, only ER-positive BCs generally harbor the CAV1
P132L mutation. Taking into account that CAV1 is
associated with BC recurrence and almost half of ER-
positive patients developed tamoxifen resistance, CAV1
P132L mutation has been suggested as a predictor of poor
response to this drug (46, 62).
In addition, there is growing recognition that the tumor
microenvironment can influence tumor cell behavior,
where fibroblasts are involved as key modulators of cancer
progression (20, 21). Breast tumors grown in a CAV1-
deficient microenvironment were more than five-fold larger
than tumors grown in a wild-type CAV1-containing
microenvironment. Thus, a CAV1-deficient tumor
microenvironment provides fertile niche for BC growth
(63). The role of CAV1 in cancer was strictly focused on
its epithelium-dependent functions, while completely
overlooking its effect on the tumor-associated stroma.
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CAV1 has recently emerged as a novel stromal regulator
of cancer growth and has been named “stromal gate
keeper” (64, 65). Human BCAFs are a subpopulation of
fibroblasts that function as supporting cells for cancer
progression and provide recycled nutrients to tumor cells.
CAV1-deficient CAFs are implicated in the Reverse
Warburg Effect (66, 67). This model is based on the
original Warburg effect, according to which tumor
metabolism switches from oxidative phosphorylation to
aerobic glycolysis in order to fuel its own growth. The
revolutionary difference is that the Warburg effect occurs
in fibroblasts, not in cancer epithelial cells (56). MCF7
cells are able to induce oxidative stress in tumor-adjacent
stromal cells that drive the loss of stromal CAV1 in
adjacent BCAFs (68). Studies demonstrated that the loss
of CAV1 in stromal cells induced the ligand-independent
activation of the transforming growth factor beta (TGFβ)
pathway and that CAV1−/− stromal cells exhibited up-
regulation of 35 transcripts associated with activated TGFβ
signaling, including the TGFβ target gene CTGF (69). It
was also shown that a loss of stromal CAV1 induces the
metabolic reprogramming of CAFs with the induction of
glycolysis and autophagy (70-72).
The role of CTGF in BC remains controversial. It has
both a tumor-promoting and tumor-suppressor role and
exerts compartment-specific actions. Overexpression of
CTGF in BC epithelial cells inhibited tumor growth, but
on the contrary, a tumor-promoting effect was observed
when CTGF was overexpressed in the tumor fibroblast
compartment (73-76). CTGF drives the induction of
autophagy in both fibroblasts and BC cells through
increased oxidative stress and hypoxia inducible factor 1
alpha subunit (HIF1α) stabilization (72). More specifically,
CTGF-induced autophagy in CAFs is mediated by
mitochondria and thus these cells are forced to undergo
aerobic glycolysis. Through this type of metabolic
pathway, stromal cells are able to produce elevated levels
of L-lactate and pyruvate, becoming a source of fuel for
epithelial cancer cells, which become the recipients of
stromal catabolites. Conversely, the induction of CTGF-
mediated autophagy in epithelial tumor cells may cause
self-digestion and inhibition of tumor growth. In
conclusion, in the absence of CAV1, CAFs (with the
overexpression of CTGF) derived from patients with BC
are able to feed epithelial cancer cells with recycled
nutrients through metabolic reprogramming of the tumor
stroma, driving tumor development without increased
neovascularization (77). These data may suggest the use of
new therapies, excluding angiogenesis inhibitors when they
do not work, and indicate the need for use of antioxidants
and autophagy inhibitors to prevent oxidative stress in
tumor fibroblasts, cutting off the fuel supply to cancer
cells (78-79).
The Role of CAV1 in Radiobiological 
Responses of Tumor Cells
Radiation therapy (RT) is one of the most important
modalities for treating many types of cancers, including
those of the breast, whose goal is local control of the cancer
at the site of the tumor (80). Tumor radioresistance and
radiosensitivity of normal tissues are the major objects of
research in radiobiology. Ionizing radiation (IR) (such as X-
rays or high-energy electrons) induces high stress levels in
both tumor and normal cells, many of which are dependent
upon cell type, genetic background, dose, dose rate and time
after irradiation (80-81).
The knowledge in the field of genetics, cell and molecular
radiobiology may enable for new approaches to research for
developing innovative and predictive tests of radiosensitivity
of tumors and normal tissues. Consequently, research efforts
are targeted at improving the effects of radiotherapy and
realizing greater individualization of treatments.
In recent years, the molecular mechanisms through which
CAV1 is involved in radio-and chemoresistance of cancer cells
have been increasingly explored. Hehlgans et al. reported
radiosensitization and anti-proliferative effects by siRNA-
mediated knockdown of CAV1 in some cancer cell lines, such
as Mia PaCa2, Panc1 and PATU8902 (82). Expression of
CAV1 was reported to be elevated in cells exposed to IR and
its overexpression conferred radioresistance to these cell lines
(83). The up-regulation of CAV1 protein in response to DNA-
damaging agents such as IR plays an important role in
activating the DNA-repair signaling cascade and in promoting
the repair of double-strand breaks, through both homologous
recombination and non-homologous end joining, thus
contributing to the maintenance of genomic integrity. The role
of CAV1 in homologous recombination has been shown in the
MDA-MB-468 BC cell line transfected with a CAV1 siRNA
and irradiated with 5 Gy of IR. Its effect might be related to
the accumulation of BRCA1 foci in the nucleus after DNA
damage. BRCA1 is a DNA-repair protein whose expression is
controlled by CAV1. In addition, a role of CAV1 in non-
homologous end joining has been recorded. Indeed,
suppression of CAV1 by siRNA in MDA-MB-468 cells
dramatically inhibited the IR-activated phosphorylation
(Ser2056) of protein kinase DNA-activated catalytic
polypeptide (alias DNA-PK), one of the key factors of the
non-homologous end joining system (83).
Unexpectedly, CAV1 was up-regulated within 30 min
following IR treatment, a time much earlier than the 24 h as
shown in pancreatic carcinoma cell lines. These data suggest
that CAV1 may act as a sensor and early mediator in
response to DNA damage and that it could be activated
before Ataxia telangiectasia mutated (ATM), the key protein
kinase activated by DNA damage (83). In MDA-MB-468
cells with CAV1 silenced, after 5 Gy IR exposure, the activity
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of ATM was lower than that in control cells, as demonstrated
by decreased levels of phospho-ATM (Ser 1981) and
phospho-checkpoint kinase 2 (CHK2) (Thr 68), the
downstream target of ATM. Cell treatment with inhibitors of
PP2 (SRC tyrosine kinase inhibitor), a phosphatase that
reduces ATM phosphorylation, was able to augment the IR-
induced phosphorylation of ATM, indicating the involvement
of PP2A in the regulation of ATM activity following DNA
damage. Co-immunoprecipitation experiments demonstrated
an increased physical association between CAV1 and PP2A
after treatment with IR. These results suggest that in
response to DNA damage, CAV1 plays an essential role in
activating the ATM-initiated repair pathway by sequestering
and inhibiting the function of PP2A (82, 83).
Nowadays, new therapeutic opportunities and technologies
using IR are available in supporting anti-BC treatment. An
example is intraoperative electron radiation therapy (IOERT),
consisting of the irradiation of the tumor site after surgical
removal to destroy residual cancer cells and to avoid tumor
relapse, with a unique delivery of a high dose (exclusive
treatment of 21-23 Gy) or of a lower one (boost treatment of
9-12 Gy) according to specific clinical features of BC (84).
In order to study molecular mechanisms activated by IR
during IOERT treatment and to select potential new
biomarkers of radiosensitivity or radioresistance, our
research group performed gene-expression profiling by
cDNA microarrays in BC cell lines irradiated with 9 and 23
Gy doses. We observed consistent differences among the
types of treatment and cell lines used, and the magnitude of
transcriptional variation was cell type-specific and dose-
dependent. In the MCF7 BC cell line, we reported that high
IR dose treatment up-regulated CAV1 transcriptional levels.
Based on microarray results and on an as yet not understood
role of CAV1 in BC cell response to IR, we analyzed CAV1
protein localization in cholesterol and glycosphingolipid-
enriched membrane microdomains, the lipid rafts. In MCF7
cells treated with 9 Gy, we observed a significant recruitment
of CAV1 to the low-density fractions containing the lipid raft
compartments with respect to untreated MCF7 cells (85).
Our data showed an increase of the CAV1 lipid raft
localization following IOERT irradiation, suggesting its role
as a biomarker of radiosensitivity, since it could contribute
to cell death after high-dose IR treatment (85).
CAV1, EGFR and RT
Many tumor cells are characterized by overexpression of
EGFR, a protein that promotes growth, aggressiveness and
resistance of cancer cells to chemotherapy and RT (86-88).
EGFR can be phosphorylated in response to binding of its
specific ligands (EGF, TGFα and amphiregulin) (89, 90) and
after exposure to non-specific stimuli such as IR, UV-
radiation, hypoxia, hyperthermia, oxidative stress and
transactivation by G-protein-coupled receptors (91-97). In
these cases EGFR phosphorylation resulted in receptor
internalization and intracellular signaling (98), causing its
silencing and inactivation (88, 99-101). The two features
involved in EGFR internalization are the clathrin-coated pit
and CAV1-driven internalization (59, 102-103). The first is
associated with EGFR internalization following treatment
with EGF (95). Exposure to oxidative stress can lead to
internalization of EGFR by caveolae and this process is
associated with perinuclear accumulation of EGFR (104). IR
leads to a fast activation of SRC, by autophosphorylation of
Y416 residue of EGFR (9, 95). IR exposure also mediates the
SRC-driven phosphorylation of EGFR at the Y485 residue
and of CAV1 at Y14, an event necessary for EGFR
internalization into caveolae. Caveolar compartmentation
prevents EGFR degradation and simultaneously enables
intracellular EGFR signaling (96). Additional EGFR function
is further supported by the observation that perinuclear EGFR
can be translocated to the nucleus in response to IR. EGFR
internalization occurs predominantly following treatment of
cells with genotoxic agents, suggesting that internalization
and nuclear transport of EGFR are linked with DNA repair
processes (105, 106). This assumption is supported by the
finding that CAV1-mediated EGFR internalization was not
observed in the A549 cell line after EGF treatment (105). In
HH4dd and FaDu cell lines irradiated with a single dose of 4
Gy and MDA-MB-468 BC cells irradiated with a single dose
of 5Gy, CAV1 controlled non-homologous end joining,
modulating the activity of DNA-PK, via CAV1-mediated
nuclear translocation of EGFR (84, 88). Indeed, nuclear
EGFR is linked with the activation of DNA-PK (detected by
phosphorylation at T2609) and with the regulation of non-
homologous end joining, resulting in increased
radioresistance (88). Detection of nuclear EGFR in tumor
biopsies correlated strongly with resistance to treatment and a
poor prognosis (87). These findings suggest a new function
of EGFR depending on its intracellular localization. In
response to radiation, not only SRC-dependent EGFR
phosphorylation at Y485, but also autophosphorylation at
Y992 and Y1173 were observed (105). This finding implies
that IR may activate not only SRC kinase, but also EGFR
kinase, and both kinases contribute to alter the EGFR
phosphorylation pattern following radiation exposure. In
A549 and FaDu cell lines, inhibition of SRC activity was
shown, with the block of CAV1-dependent EGFR
internalization and nuclear transport after irradiation. In
addition, activation of DNA-PK was abolished, DNA-repair
inhibited and radiosensitivity increased (105). CAV1-targeted
siRNA also inhibited the co-translocation of CAV1 and EGFR
in MDA-MB-468 cells following IR treatment (84). This
EGFR-coupled radiation response mechanism offers new
potential molecular targets for cancer treatment and patient
care, especially for radiation therapy.
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Conclusion 
The choice of a single therapy common to all patients is not
possible because of the presence of several types and sub-types
of BC. Today, the therapeutic choices used for the treatment of
BC are different. CAV1 is emerging as a potential biomarker
in BC. Figure 1 summarizes the roles of CAV1 in BC. From
its newly-found roles in BC both in cancer epithelium and
tumor stroma, CAV1 may be useful as a prognostic indicator
for patient treatment, and to help clinicians in the choice of the
best personalized therapy and in optimizing results.
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